This is a single arm, open label study of up to 24 prostate cancer patients scheduled for prostatectomy and/or pelvic lymph node dissection. Patients receive a single IV dose of 99mTc-MIP-1404 (study drug) followed by SPECT/CT scan 3-6 hours after injection. As standard of care, patients will undergo prostatectomy and/or pelvic lymph node dissection (PLND) within two weeks of study drug dosing. 99mTc-MIP-1404 image data will be evaluated for visible uptake and compared with histopathology.

Inclusion Criteria:

• Male aged 21 years or older.
• Ability to provide signed informed consent and willingness to comply with protocol requirements.
• Past biopsy indicating the presence of adenocarcinoma of the prostate gland.
• Participant is deemed to have tissue suspicious of prostate cancer involvement that is amenable to biopsy/resection.
• Have had, or will undergo diagnostic CT or MRI imaging prior to surgery.
• Participants must agree to use an acceptable form of birth control throughout the study period. Participants must use condoms for a period of seven days after study drug administration, if engaged in sexual activity.

Exclusion Criteria:

• Participants for whom participating would significantly delay the scheduled standard of care therapy.
• Participants administered a radioisotope within 5 physical half lives prior to study enrollment.
• Participants with any medical condition or other circumstances that, in the opinion of the investigator, would significantly decrease obtaining reliable data, achieving study objectives or completing the study.